Akebia Ther Stock Investor Sentiment

AKBA Stock  USD 2.04  0.09  4.23%   
About 65% of Akebia Ther's investor base is looking to short. The analysis of the overall investor sentiment regarding Akebia Ther suggests that many traders are alarmed. The current market sentiment, together with Akebia Ther's historical and current headlines, can help investors time the market. In addition, many technical investors use Akebia Ther stock news signals to limit their universe of possible portfolio assets.
  

Akebia Ther Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Akebia Ther can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at finance.yahoo.com         
Akebia Therapeutics, Inc. Released Earnings Last Week And Analysts Lifted Their Price Target To US4....
Yahoo News
over six months ago at finance.yahoo.com         
Akebia Therapeutics Full Year 2023 Earnings EPS Beats Expectations
Yahoo News
over six months ago at investorplace.com         
Acquisition by Snow Ellen of 224000 shares of Akebia Ther at 1.68 subject to Rule 16b-3
sbwire news
over six months ago at investorplace.com         
AKBA Stock Earnings Akebia Therapeutics Beats Revenue for Q4 2023
sbwire news
over six months ago at gurufocus.com         
Akebia Therapeutics Inc Reports Steady Revenue and a Profitable Quarter
Gurufocus Stories at Macroaxis
over six months ago at seekingalpha.com         
Akebia GAAP EPS of 0.00 beats by 0.04, revenue of 56.2M beats by 0.81M
seekingalpha News
over six months ago at finance.yahoo.com         
Akebia Therapeutics Reports Break-Even Earnings for Q4
Yahoo News
over six months ago at finance.yahoo.com         
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
Yahoo News
over six months ago at www.macroaxis.com         
Acquisition by Nicole Hadas of 200000 shares of Akebia Ther subject to Rule 16b-3
Macroaxis News
over six months ago at zacks.com         
Rigel Pharmaceuticals Reports Break-Even Earnings for Q4
zacks News
over six months ago at news.google.com         
Akebia Therapeutics, Inc. Short Interest Down 8.9 percent in February - MarketBeat
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
Insider Selling Akebia Therapeutics, Inc. CEO Sells 57,354.16 in Stock
news
over six months ago at thelincolnianonline.com         
Akebia Therapeutics, Inc. CEO John P. Butler Sells 46,570 Shares
news
over six months ago at thelincolnianonline.com         
Akebia Therapeutics, Inc. COO Michel Dahan Sells 10,744 Shares of Stock
news
over six months ago at finance.yahoo.com         
Disposition of 8661 shares by Michel Dahan of Akebia Ther at 1.58 subject to Rule 16b-3
Yahoo News
Far too much social signal, news, headlines, and media speculation about Akebia Ther that are available to investors today. That information is available publicly through Akebia media outlets and privately through word of mouth or via Akebia internal channels. However, regardless of the origin, that massive amount of Akebia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Akebia Ther news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Akebia Ther relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Akebia Ther's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Akebia Ther alpha.

Akebia Ther Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo for Patients on Dialysis
10/07/2024
2
CMS Grants TDAPA Reimbursement for Vafseo beginning January 1, 2025
10/10/2024
3
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo for Patients on Dialysis
10/22/2024
4
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
11/01/2024
5
Acquisition by Rogers Michael W of 30000 shares of Akebia Ther subject to Rule 16b-3
11/05/2024
6
Akebia Q3 2024 Earnings Preview
11/06/2024
7
Akebia GAAP EPS of -0.10, revenue of 37.4M
11/07/2024
8
Akebia Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Revenue Challenges ...
11/08/2024
9
Q3 2024 Earnings Hold Akebia Therapeutics - Seeking Alpha
11/20/2024
10
Akebia Therapeutics, Inc. Sees Large Decline in Short Interest
12/02/2024

Complementary Tools for Akebia Stock analysis

When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Money Managers
Screen money managers from public funds and ETFs managed around the world
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance